EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Innovative β-lactams and β-lactam/β-lactamase inhibitor combinations against carbapenemase-producing Enterobacterales

Jorge Arca-Suárez iD, Tania Blanco-Martín iD, Lucía González-Pinto iD, Salud Rodríguez-Pallares iD, Juan Carlos Vázquez-Ucha iD, Alejandro Beceiro iD, Concepción González-Bello iD, Germán Bou iD

Clinical Microbiology Reviews · 06.11.2026

DOI: 10.1128/cmr.00117-25 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Microbiology Reviews, online erschienen am 06.11.2026. Verfasst von Jorge Arca-Suárez und 7 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Microbiología Clínica & Grupo de Investigación en Microbiología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hosp…. Die Arbeit nennt 318 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Xunta de Galicia, Ministerio de Ciencia e Innovación.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The global dissemination of carbapenemase-producing Enterobacterales (CPE) represents one of the most pressing threats to modern antimicrobial therapy. The rapid worldwide expansion of these organisms has been driven by the emergence and successful dissemination of diverse carbapenemases belonging to Ambler classes A, B, and D, including KPC, OXA-48-like, and metallo-β-lactamases, such as NDM, VIM, and IMP. These enzymes severely compromise the activity of carbapenems, historically considered the cornerstone for treatment of severe infections caused by multidrug-resistant Gram-negative bacteria. In response to this growing challenge, substantial efforts in antibiotic discovery have led to the development of several novel β-lactams and β-lactam/β-lactamase inhibitor combinations specifically designed to restore activity against carbapenem-resistant Enterobacterales (CRE). This review provides a comprehensive microbiological overview of recently approved and investigational agents targeting CPE. We examine the structural and mechanistic features of key therapeutic options, including cefiderocol and multiple β-lactam/β-lactamase inhibitor combinations incorporating classical penicillin-based sulfone derivatives, diazabicyclooctanes, and cyclic boronates. Particular attention is given to the biochemical properties and inhibitory spectra of β-lactamase inhibitors, as well as the antimicrobial activity of novel β-lactams and β-lactam/β-lactamase inhibitor combinations against both isogenic strains and large collections of clinical Enterobacterales isolates. In addition, we discuss the emerging resistance mechanisms that may compromise the clinical effectiveness of these agents. Understanding the mechanistic basis of both activity and resistance is essential to guide their optimal therapeutic positioning and to inform the next generation of antimicrobial development aimed at combating the ongoing threat of CRE.

Schlagwörter

Stichwörter der Autor:innen

Enterobacteralesantimicrobial resistanceboronatecarbapenemasediazabicyclooctanedrug resistance mechanismsβ-lactamβ-lactam/β-lactamase inhibitor combinationsβ-lactamaseβ-lactamase inhibitor

Autor:innen und Institutionen

  • Servicio de Microbiología Clínica & Grupo de Investigación en Microbiología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), SERGAS, Universidade da Co…
  • CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
  • Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Departamento de Química Orgánica, Universidade de Santiago de Compostela, Santiago de Compostela, Spain.
  • Departamento de Fisioterapia, Medicina y Ciencias Biomédicas, Universidad de A Coruña, A Coruña, Spain.

ORCID-Profile: Jorge Arca-Suárez, Tania Blanco-Martín, Lucía González-Pinto, Salud Rodríguez-Pallares, Juan Carlos Vázquez-Ucha, Alejandro Beceiro, Concepción González-Bello, Germán Bou

Förderung

  • Instituto de Salud Carlos III
  • Xunta de Galicia
  • Ministerio de Ciencia e Innovación

Zitieren

APA

Arca-Suárez, J., Blanco-Martín, T., González-Pinto, L., Rodríguez-Pallares, S., Vázquez-Ucha, J. C., Beceiro, A., González-Bello, C., & Bou, G. (2026). Innovative β-lactams and β-lactam/β-lactamase inhibitor combinations against carbapenemase-producing Enterobacterales. Clinical Microbiology Reviews. https://doi.org/10.1128/cmr.00117-25

Vancouver

Arca-Suárez J, Blanco-Martín T, González-Pinto L, Rodríguez-Pallares S, Vázquez-Ucha JC, Beceiro A, et al. Innovative β-lactams and β-lactam/β-lactamase inhibitor combinations against carbapenemase-producing Enterobacterales. Clinical Microbiology Reviews. 2026. doi:10.1128/cmr.00117-25

BibTeX
@article{ArcaSurez2026,
  author = {Arca-Suárez, Jorge and Blanco-Martín, Tania and González-Pinto, Lucía and Rodríguez-Pallares, Salud and Vázquez-Ucha, Juan Carlos and Beceiro, Alejandro and González-Bello, Concepción and Bou, Germán},
  title = {Innovative β-lactams and β-lactam/β-lactamase inhibitor combinations against carbapenemase-producing Enterobacterales},
  journal = {Clinical Microbiology Reviews},
  year = {2026},
  doi = {10.1128/cmr.00117-25}
}
Kostenlos starten →